There are many patient communities across various races and ethnicities that are often underrepresented in clinical trials, which creates significant gaps in the safety and efficacy data of new therapies.
Labcorp Drug Development offers a comprehensive solution to clients seeking to harness the power of genomic- and proteomic-based profiling to support clinical development programs.
Hear Kathy Landshulz, Therapeutic Area Lead, Biomarker Solution Center, Labcorp Oncology, keynote presentation from the World CDx US 2022 conference, "Practical Strategies for Implementing an Effective Neurodegenerative Biomarker Program into Your Clinical Trial and Diagnostic Transition."
The presentation covers deploying the right biomarkers, platforms
Listen to Maryland Franklin, PhD, Vice President and Enterprise Head of Cell & Gene Therapy, Labcorp Drug Development, focus on addressing the complexity of long-term follow up for cell and gene therapy with a patient-guided approach in her presentation, Taking the Long View: Addressing the Unique Challenge of Long-Term Follow Up for Cell & Gene Th
The webinar covers the current lessons learned from recent CF trials, barriers faced in today's research landscape, and several approaches to handle common issues.
How do you identify the right patient for a given drug? How do you select your population to ensure that the signal of benefit is most pronounced? The boundaries of breast cancer biomarker development are being increasingly pushed to help power better decisions for developers, oncologists and, ultimately, for breast cancer patients.
The critical need for potent SARS-CoV-2 treatments has required acceleration of development timelines without compromising safety. Learn how one biotech company was able to administer the first human dose of a new antiviral just 23 days after first meeting with the CRO.
From revealing phenotypic and functional characterization of CAR T-cell products, along with mechanistic markers of efficacy and predictive markers of safety and response, biomarkers of all types play a central role in delivering critical insights that support informed decisions at every step of therapeutic development.
Over the last decade, an increasing number of drug development sponsors have conducted endometriosis clinical trials to explore more specific therapeutic targeting approaches for this chronic disease.